This inventor holds 1 USPTO granted patent. Top assignees: Kolon Life Science, Inc., Kolon Tissuegene, Inc.. Active years: 2026.
Company Filing History:
1 out of 10 
1 out of 6 Years Active: 2026
Title: The Innovations of Soon Dong Lee
Introduction
Soon Dong Lee is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of osteoarthritis. His innovative approach combines advanced cellular techniques to enhance therapeutic outcomes for patients.
Latest Patents
Soon Dong Lee holds a patent for a pharmaceutical composition aimed at preventing or treating osteoarthritis. This composition includes cells or cell groups that are of a specific size or less. The mixed cells, which are selected based on their size, consist of transformed mammalian cells with TGF-β and untransformed mammalian cells. This unique combination minimizes aggregation between chondrocytes and provides beneficial therapeutic effects. Furthermore, administering these selected mixed cells to patients can improve compliance and facilitate quality management in therapeutic agent manufacturing facilities or hospitals.
Career Highlights
Throughout his career, Soon Dong Lee has worked with prominent companies in the biotechnology sector, including Kolon Life Science, Inc. and Kolon Tissuegene, Inc. His work in these organizations has allowed him to develop and refine his innovative approaches to pharmaceutical compositions.
Collaborations
Some of his notable coworkers include Ha Eun Kim and Hyeon Youl Lee. Their collaborative efforts have contributed to the advancements in the field of osteoarthritis treatment.
Conclusion
Soon Dong Lee's contributions to pharmaceutical innovations, particularly in the treatment of osteoarthritis, highlight his role as a significant inventor in the field. His patented work demonstrates the potential for improved patient outcomes through innovative cellular therapies.